Shilpa Medicare Limited (BOM:530549)
278.55
-11.40 (-3.93%)
At close: Jan 20, 2026
Shilpa Medicare Revenue
Shilpa Medicare had revenue of 3.70B INR in the quarter ending September 30, 2025, with 7.61% growth. This brings the company's revenue in the last twelve months to 13.43B, up 10.42% year-over-year. In the fiscal year ending March 31, 2025, Shilpa Medicare had annual revenue of 12.88B with 11.69% growth.
Revenue (ttm)
13.43B
Revenue Growth
+10.42%
P/S Ratio
3.94
Revenue / Employee
13.46M
Employees
998
Market Cap
52.93B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2025 | 12.88B | 1.35B | 11.69% |
| Mar 31, 2024 | 11.53B | 1.01B | 9.64% |
| Mar 31, 2023 | 10.52B | -952.56M | -8.31% |
| Mar 31, 2022 | 11.47B | 2.45B | 27.21% |
| Mar 31, 2021 | 9.02B | -66.41M | -0.73% |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| IOL Chemicals and Pharmaceuticals | 21.70B |
| Neuland Laboratories | 15.33B |
| Bajaj HealthCare | 6.11B |
| Sudeep Pharma | 5.61B |
| NGL Fine-Chem | 4.08B |
| Infinium Pharmachem | 1.57B |
| Gujarat Themis Biosyn | 1.55B |
| Anlon Healthcare | 1.44B |
Shilpa Medicare News
- 6 weeks ago - Shilpa Medicare receives Initial Authorization for Rotigotine transdermal patch in European - Business Upturn
- 2 months ago - Shilpa Medicare Ltd (BOM:530549) Q2 2026 Earnings Call Highlights: Record EBITDA and Strategic ... - GuruFocus
- 2 months ago - Q2 2026 Shilpa Medicare Ltd Earnings Call Transcript - GuruFocus
- 2 months ago - Shilpa Medicare launches world’s first NODUCA Therapy for MAFLD after CDSCO approval - Business Upturn
- 2 months ago - Shilpa Medicare Q2 Results: Net profit jumps 144% YoY to Rs 44 crore, revenue up 7.6% - Business Upturn
- 2 months ago - Shilpa Medicare shares jump nearly 3% after positive Phase 3 results for once-weekly Ondansetron injection OERIS™ - Business Upturn
- 2 months ago - Shilpa Medicare announces positive Phase 3 results for OERIS™ — once-weekly Ondansetron injection for chemotherapy-induced nausea and vomiting - Business Upturn
- 2 months ago - Shilpa Pharma Lifesciences wins EcoVadis Gold Medal for excellence in sustainability - Business Upturn